Mission Statement
To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions.

NEWS

19th Jul 2018 Proposed placing and subscription to raise up to £10.6 million
13th Jul 2018 Hardman & Co Research
12th Jul 2018 Trading update
25th Jun 2018 Positive data of Pollinex Quattro Grass vaccine
29th May 2018 Positive data with house-dust mite immunotherapy
21st May 2018 Positive top-line results from Grass Ph II study
14th May 2018 Publication of MCT Adjuvant Data
07th Mar 2018 Hardman Research: Clinical development towards submission
07th Mar 2018 Interim Results for the six months ended 31 December 2017


VIDEO/AUDIO
21st May 2018 Allergy Therapeutics on track for phase III grass pollen trial in 2019
September 2017 5 minute pitch
09th May 2016 Allergy Therapeutics boss excited by PQBirch204 Phase II data
08th Mar 2016 Allergy Therapeutics says double-digit revenue growth is sustainable
18th Feb 2016 Allergy Therapeutics hopes to launch "exciting" grass pollen allergy vaccine in 2019
14th Jan 2016 Allergy Therapeutics boss says the firm is outperforming its competitors

EVENTS
27 11 2018 AGM (tentative)
03 10 2018 Shares Investor Evening (London)
26 09 2018 Preliminary Annual Results 2018 Announcement (tentative)


WEBSITES

19 October 2017
Allergy Therapeutics plc

Commencement of dosing in PQ Grass Phase II Trial

19 October 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that dosing has commenced in its G205 Phase II study designed to evaluate the dose-response and safety of its ultra-short course, aluminium free PQ Grass immunotherapy to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

The study is anticipated to run for one year and involve approximately 440 patients in more than 50 sites across Germany, Austria and Poland. The trial is designed to identify the optimal efficacious cumulative dose using conjunctival provocation testing. This type of challenge testing has recently been used in studies for a similar subcutaneous birch pollen product resulting in selection and approval of dose for use in a current phase III study. The results of the G205 trial are expected in H2 2018. Following completion of this trial, meetings with the regulatory authorities in the US and Germany will be necessary to enable Phase III trial design.

The US allergy immunotherapy market, which is anticipated to be the main market for this product, is estimated by the Group to be worth $2 billion with potential peak grass vaccine sales of $300-400 million per annum. If approved, the product will be the first registered subcutaneous immunotherapy product in the US for allergy.


Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "The start of treatment in this important Phase II trial marks an exciting and critical period of trials for the Group's research and development pipeline. This trial aims to strengthen the Group's portfolio in Europe and the US and takes us another step closer to treating patients in the major US market."

http://www.moneyam.com/action/news/showArticle?id=5709529

Missed yesterdays 16:14 announcement:

19 October 2017


Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")


ANNUAL FINANCIAL REPORT 2017 AND NOTICE OF 2017 ANNUAL GENERAL MEETING


Allergy Therapeutics Plc has today published the following documents:

· Annual Report for the year ended 30 June 2017 ("Annual Report"); and

· Notice of 2017 Annual General Meeting ("Notice of Meeting");

Each of these documents is available electronically on the Company's website at www.allergytherapeutics.com

A hard copy of the Annual Report and Notice of Meeting is anticipated to be posted to shareholders on 19 October 2017.

http://www.moneyam.com/action/news/showArticle?id=5711023


Annual Report for the year ended 30 June 2017

Allergy Therapeutics - strong financial showing, solid cash position, progress in the clinic
10:08 20 Oct 2017

Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank



Allergy Therapeutics PLC’s (LON:AGY) preliminary results charted a period of strong financial and operational progress with the company predicting further progress on all fronts this year.

Operating profits (pre-research and development expenditure) rose 72% in the 12 months to June 30 on revenues of £64.1mln, up 32%. The latter figure did benefit from a boost from the weak pound. Even so, at constant currencies, top-line growth was a solid 15%.

WATCH: Allergy preparing the ground for big opportunities in the US

Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank.

Strong cash position

That cash will be important when it comes to funding its research programmes.

It has started the recruitment for a Phase III clinical trial of Pollinex Quattro for those with an allergy to birch pollen.

The programme for the Grass MATA MPL product is “proceeding well”, Allergy said. A US safety study has been completed and a Phase II programme is expected to get underway soon.

The first patient has been recruited for a Phase I assessment of Acarovac, for dust mite allergy, which is underway in Spain.

Further progress expected

The allergy treatment specialist has also received positive pre-clinical proof of concept data announced for Polyvac for a reaction to peanuts.

“Our continuing growth and progress on our pipeline reflects the quality of the products and the committed team that works at Allergy Therapeutics,” said chief executive Manuel Llobet.

“We expect further good progress in the coming year."

Minor tweaks

The broker FinnCap said it had made only minor tweaks to its forecasts following the results.

It expects revenues to rise to £72.5mln. Its price target is 47p a share (current price 32.8p).

Market share gains

Finncap sees Allergy with a market share of about 16% in 2020, which equates to revenues of €97mln in a market that the broker estimates will be worth €605mln, assuming market growth over 2017-2020 of 3% per annum.

This is set against the company's aspirational target of “20% in 2020".

An additional 4% share in 2020/21 would imply revenues some €20m higher than currently forecast, which would add a further 10p to the target valuation.

Market share in the yar to Juen just ended grew by 100bps (1%) to about 13% making a gain of 300bps since 2015 in a market that is broadly flat.

Growth was strong in Spain (+13%), Holland (+29%), Austria (+27%) and Germany (+13%).

An 80-year history

Allergy Therapeutics has an 80-year history and so is no “jam tomorrow” drug development company.

It has a profitable core business and, a number of ground-breaking allergy vaccines that trade under various brand names.

READ: Allergy Therapeutics strengthens clinical research team with senior appointments

Its most commonly prescribed vaccines are used to treat pollen-related allergies, particularly allergies to grasses and trees.

It has a strong presence in Europe with established operations in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the United Kingdom, while in other markets it often makes its products available through distribution partners.

Its Pollinex Quattro vaccine for the treatment of seasonal allergic rhinitis (hay fever) from grass, tree or ragweed pollen allergy is already established in Europe, and the company wants to replicate that in the US, where it will enjoy first mover advantage in a market potentially worth £1.5bn ($2bn).

- -updated October for new finncap comment--


http://www.proactiveinvestors.co.uk/companies/news/184731/allergy-therapeutics-strong-financial-showing-solid-cash-position-progress-in-the-clinic-184731.html

13 November 2017
Allergy Therapeutics plc

Allergy Therapeutics to Present at Jefferies 2017 London Healthcare Conference

13 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that Manuel Llobet, Chief Executive Officer, will be presenting at the Jefferies 2017 Healthcare Conference in London, on Wednesday 15 November at 13:20 GMT.

http://www.moneyam.com/action/news/showArticle?id=5739958

Jefferies 2017 London Healthcare Conference

November 15-16, 2017
London, UK

The Jefferies 2017 London Healthcare Conference will be taking place November 15-16 in London, UK.

Now in its eighth year, the Jefferies Conference is the largest healthcare-dedicated conference in Europe. This year, we hosted 350 participating companies, 1,400 attendees and 3,400 investor and business-to-business meetings. The event featured leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, China and Japan.

You must be pre-registered to attend this conference. Please reach out to your Jefferies representative in order to register.

21 November 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")

Block Listing Application

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that an application has been made to the London Stock Exchange for admission to AIM for a block listing of 10,000,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares").

The new Ordinary Shares will not be allotted immediately but rather will be issued and allotted from time to time pursuant to the exercise of employee options under the Allergy Therapeutics 2013 Long Term Incentive Plan. On exercise, these new Ordinary Shares will be issued as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of the Company.

The expected effective date of admission of these securities to AIM is on or around 24 November 2017.

http://www.moneyam.com/action/news/showArticle?id=5750700

12 December 2017
Allergy Therapeutics plc

Allergy Therapeutics enters co-development agreement with Ergomed plc

12 December 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it has entered into a co-development collaboration agreement with Ergomed plc ("Ergomed") (AIM:ERGO) for the clinical development of three OralVac immunotherapy products. Allergy Therapeutics' core focus remains the convenient short course subcutaneous immunotherapy (SCIT) products, with the OralVac sublingual products providing an alternative option for patients who prefer oral products.

To capitalise on the changing regulatory requirements in Germany, the OralVac products, which are currently sold in Europe on a named patient basis, are being registered under the new TAV (Therapieallergene-Verordnung) regulation programme managed by the Paul Ehrlich Institute in Germany. The pharmaceutical development and pre-clinical evaluation for these products has already been completed by Allergy Therapeutics.

This planned OralVac clinical development expands Allergy Therapeutics' current broad SCIT clinical programme. To manage this expansion, Simon Piggott, Head of Clinical Sciences and Denise Lee, Head of Clinical Operations will lead early and late phase EU clinical development respectively, with Pieter-Jan de Kam, Clinical Director, to lead the US clinical development programme, which is focused on SCIT products and is a key part of the Group's three-pillar growth strategy.

Under the terms of the agreement, Ergomed will progress the clinical development of OralVac products for the treatment of grass pollen, tree pollen, and house dust mite allergies. The collaboration includes a future revenue share and reduced service fee.

Manuel Llobet, CEO at Allergy Therapeutics, stated: "We are pleased to announce this co-development programme with Ergomed, which is aimed at strengthening our product portfolio across Europe in a risk-sharing fashion. Ergomed has over 20 years of experience in clinical development and significant expertise in the allergy field, and are thus ideally placed to support us in the progression of our OralVac products."

http://www.moneyam.com/action/news/showArticle?id=5777145

09 January 2018
Allergy Therapeutics plc

PQ Birch Phase III clinical trial completes recruitment

9 January 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that recruitment of the Group's Phase III clinical trial with PQ Birch (PQBirch301) has been completed as expected. The PQBirch301 study is a pivotal Phase III study designed to evaluate the safety and efficacy of the Group's ultra-short course, convenient for patients, aluminium free PQ Birch subcutaneous immunotherapy to address the cause of symptoms of allergic rhinoconjunctivitis due to birch pollen.

The PQBirch301 study has randomised over 560 patients from 59 centres in four European countries: Germany, Austria, Poland and Sweden. The primary efficacy data will be assessed during the birch pollen season of 2018 and the results of the trial are expected during H2 2018. The successful completion of this pivotal Phase III study would fulfil the requirements for PQ Birch under the Therapieallergene-Verordnung (TAV) of the Paul Ehrlich Institut before anticipated marketing authorisation.

PQ Birch is one of a number of ultra-short course, subcutaneous immunotherapy products in clinical development for various allergies, and these form a key component of the Group's three-pillar growth strategy. This includes: developing a strong pipeline facilitated by investment from the growing, profitable European revenue stream; expanding the existing European business; and preparing for product entry into the US market. The PQ family of products complement the Group's existing European marketed portfolio of convenient short course subcutaneous immunotherapy products and are particularly suited to the changing regulatory environment for allergy products in the US


Approximately 6% of the population of Europe alone is allergic to birch pollen1 and there continues to be a need for a safe and well tolerated effective treatment for this significant health issue.


Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "The completion of recruitment in our pivotal Phase III clinical study with PQ Birch is an important milestone for the Group. Marketing authorisation of the first MPL-adjuvanted, ultra-short course aluminium free vaccine available to patients will strengthen the Group's portfolio and help address the current unmet needs in allergy."

1 DataMonitor Epidemiology Report. 2011

http://www.moneyam.com/action/news/showArticle?id=5807728

31 January 2018
Allergy Therapeutics plc

Trading Update

Market share gains driving top line growth

Strong cash position sustained by good performance.

31 January 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today provides a trading update for the six months ended 31 December 2017, ahead of its unaudited interim results to be announced on 7 March 2018.


Financials

The Group reports that it is trading in line with the Board's expectations. Reported revenues for the six months ended 31 December 2017 are expected to be £42.2m (2016: £40.4m), representing 4.4% growth on a reported basis and 1.3% growth at constant currency. The Group has continued to grow in the past six months of 2017, notwithstanding an abnormally weak pollen season in Central Europe1, outperforming the market by an average of 4 percentage points2 thanks to focused sales and marketing strategy and its exclusive technology platform. In Germany, the Group's market share has risen by one percentage point to 14% over the past twelve months on a moving annual average basis. The fastest growing operations for the Group in the six months ended 31 December 2017 were the Spanish subsidiary as well as the Emerging Markets segment.

By leveraging additional revenues on current infrastructure, the Group continues to improve its operational margins pre-R&D. This, along with careful planning of working capital and capex investments, has allowed the Group to maintain a strong cash position of £25.8m (31 December 2016: £27.8m).


Products

There continues to be increasing uptake of the Group's portfolio of convenient and patient-friendly treatments. Pre-seasonal ultrashort course aluminium free vaccine Pollinex Quattro, designed to address the cause of symptoms of patients sensitised to seasonal allergens (grass, trees, ragweed), remains a key growth driver for Allergy Therapeutics based on the benefits of the Group's treatment programs.

Venomil, the Group's product that treats the life threatening condition of venom allergy, grew strongly as well as Acarovac Plus3 which continued to outperform the rest of the portfolio in Spain.


Pipeline

The Group's Phase III PQ Birch trial has recently completed recruitment, with results expected in H2 2018. The successful completion of this pivotal Phase III study would fulfil the requirements for PQ Birch under the Therapieallergene-Verordnung (TAV) of the Paul Ehrlich Institute before anticipated marketing authorisation.

The PQ Grass Phase II trial continues to recruit on schedule with results also expected in H2 2018. Following completion of this trial, meetings with the regulatory authorities in the US and Germany will be necessary to enable Phase III trial design.

Additionally, all the German TAV plans are on track with the recent incorporation of the clinical development programmes for the oral vaccine Oralvac, under a co- development agreement with Ergomed announced in December 2017.


Outlook

Post the period end current trading remains positive and the Board remains confident in the outlook for the business for the remainder of the year. Allergy Therapeutics' competitive position continues to improve with increased market share, in the countries in which it operates, increasing in line with its long term plans to achieve 20% market share. Market share gains are consistent across its key European markets, notably in highly competitive markets like Spain, Germany, Austria and Holland.


Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "Our strategy to prioritise patient friendly vaccines with focus on patient compliance and improving adherence rates is demonstrating success. Our portfolio of ultra-short course vaccines is driving our market penetration in Europe and preparing the ground for a successful US entry. All our key development programmes are being executed according to plan and our long-term strategic objectives, are on track. We feel privileged to keep developing Allergy Therapeutics as we satisfy the significant unmet needs of our patients."

http://www.moneyam.com/action/news/showArticle?id=5836625

02 February 2018

Hardman Research: Growth in a tough market

Growth in a tough market: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a 'Named Patient' basis. Trials designed to obtain regulatory approval for PQ approved as a biologic in both Europe and the US are well advanced. Meanwhile, although underlying sales growth was weaker than expected in 1H'18, this was on the back of an unusually shorter and lower pollen season in central Europe, suggesting that AGY has continued to make further market share gains.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/02.02.18-growth-in-a-tough-market.pdf

http://www.moneyam.com/action/news/showArticle?id=5840974

Allergy Therapeutics plc

Completion of recruitment in PQ Grass Phase II trial

Trial running ahead of schedule with data now due in early H2 2018


12 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces that recruitment has been completed in its grass allergy Phase II study (G205), with results due ahead of expectations in early H2 2018. The trial is designed to evaluate the dose-response and safety of its ultra-short course, aluminium free PQ Grass immunotherapy to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.


The study protocol involves more than 440 patients in over 50 sites across Germany, Austria and Poland. The trial is designed to identify the optimal efficacious cumulative dose using conjunctival provocation testing. This type of challenge testing has recently been used in studies for a similar subcutaneous allergoid MPL product resulting in selection and approval of dose for use in a phase III study.


One of the key markets for this global product is expected to be the US. The US allergy immunotherapy market is estimated by the Group to be worth $2 billion with potential peak grass vaccine sales of $300-400 million per annum. If approved, the product will be the first registered subcutaneous immunotherapy product in the US for allergy.


Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "The completion of recruitment for all patients in our Phase II trial is an important step in our journey towards access to the US market in which PQ Grass has the potential to become a convenient, best in class, ultra-short course subcutaneous immunotherapy. We are pleased that the study is running ahead of schedule and look forward to seeing the results later this year."

http://www.moneyam.com/action/news/showArticle?id=5851299

Investor Evening - 7 March - London - Allergy Therapeutics, Bluejay Mining, Healthperm and Mercia Technologies

http://www.moneyam.com/InvestorsRoom/posts.php?tid=20764#lastread

28 February 2018
Allergy Therapeutics plc

Allergy Therapeutics prepares for manufacturing and clinical development of Polyvac® Peanut allergy product


- Specialist CMO AGC Biologics engaged -


28 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it has signed a contract with AGC Biologics (Heidelberg, Germany) to scale up the manufacturing of its Polyvac® Peanut product for use in clinical studies.

Pre-clinical findings using Polyvac® Peanut demonstrated protection against anaphylaxis and induction of protective immunity. It is planned that further development of this product will enable the Group to address the current unmet need. Allergy Therapeutics will now scale-up and validate the manufacturing processes for Polyvac® Peanut as part of the clinical development programme.

Food allergy, and in particular peanut allergy, is a significant and strategically important area for Allergy Therapeutics due to the serious and destabilising effects on the lives of both patients and their families. The global addressable market for therapies to help mitigate these effects is estimated at $8 billion per annum1.

AGC Biologics is a contract manufacturing organisation (CMO) specialising in expression and purification of recombinant therapies. The company has produced batches of cGMP-compliant material for a variety of pharmaceutical and biotech companies with proven operational expertise in the transfer, development, scale-up and validation of cGMP processes and has prior experience in expression of virus like particle constructs.


Manuel Llobet, CEO at Allergy Therapeutics, stated: "The disruption to patients' social and family life as a result of food allergies is significant, and we are committed to addressing these current unmet needs. The Group's peanut vaccine programme complements our current marketed range of ultra-short course vaccines in terms of safety, efficacy and improved patient convenience. We are pleased to start working with AGC Biologics in order to further progress the clinical programme."

http://www.moneyam.com/action/news/showArticle?id=5872398

Unless I made a mistake AGY have changed their tentative Interim Results date from the 8th to the 7th:

07 03 2018 Interim Results 2018 Announcement (tentative)

http://www.allergytherapeutics.com/investor-relations/financial-calendar/


Hmmm, which now ties in with

Investor Evening - 7 March - London - Allergy Therapeutics, Bluejay Mining, Healthperm and Mercia Technologies
http://www.moneyam.com/InvestorsRoom/posts.php?tid=20764#lastread

and te start of the European Drug Safety Summit 2018
http://www.wplgroup.com/aci/event/european-drug-safety-summit/

Just had a quick check on AGY global sites and the Italy one has changed address and has a new look:



The Germany/Austria site has same address but new look:




There is now a Swiss site:

On 1.11.2017 we renamed the company Teomed AG to Bencard AG.

https://bencard.ch/

07 March 2018

Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session, at 0930 GMT today. Dial-in details are: +44 (0) 1452 580733. Conference ID: 2485568.

Allergy Therapeutics plc

Interim Results for the six months ended 31 December 2017


- Consistent performance driven by market share gains

- Pivotal year with Grass MATA MPL readout due in H2 2018

7 March 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2017.

Highlights (including post period end highlights)


Financial highlights

· Reported revenue increased by 4.4% to £42.2m (H1 2017: £40.4m) and to £40.9m at constant currency*, representing 1.3%** growth despite an abnormally weak pollen season

· R&D expenditure increased to £5.9m (H1 2017: £3.8m) due to investment in the Grass MATA MPL Phase II and PQ Birch Phase III trials

· 12% growth in pre-R&D operating profit to £12.3m (H1 2017: £11.1m) as a result of broad investment in the business and the strength of the euro against sterling

· Strong cash balance of £25.8m (H1 2017: £27.8m)



Operational highlights

· Increased market share in the German market to 14% (2017: 13%)

· Breadth of portfolio demonstrated by strong performance from Venomil and Acarovac Plus

· Completion of recruitment in the pivotal Pollinex Quattro Birch Phase III study for Europe

· Completion of recruitment ahead of schedule for the Grass MATA MPL Phase II dosing trial for the US

· Contract for scaling up the Polyvac® Peanut product signed with AGC Biologics, aiming for first in human trials in 2019

· Acarovac Phase I trial continues with readout expected in H1 2019

· Contract for joint development of Oralvac products in the TAV process signed with Ergomed

· Bencard Adjuvant Systems continues to build its IP assets with microcrystalline tyrosine manufacturing process patented in key worldwide markets



Commenting on the interim results, Manuel Llobet, Chief Executive Officer, said: "2018 is set to be a pivotal year for Allergy Therapeutics with the key Grass MATA MPL Phase II trial on course for readout in the second half of the calendar year. This could provide us the platform to expand into the lucrative US market. In the first half of this year, we continued to outperform the wider market and delivered an increase in revenue at constant currency despite an abnormally weak pollen season, demonstrating the strength of our differentiated products. This reflects the quality of the Group's highly convenient, ultra-short course, aluminium-free therapy, enabling us to continue to gain market share."

This announcement contains insider information for the purposes of Article 7 of Regulatory (EU) No596/2014.

* Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year on year comparison excluding the effects of foreign exchange movements. See table in financial review for an analysis of revenue.

** Percentage based on figures in thousands (2017: £40.956m, 2016: £40.427m)

http://www.moneyam.com/action/news/showArticle?id=5882305

A reminder:

Investor Evening - 7 March - London - Allergy Therapeutics, Bluejay Mining, Healthperm and Mercia Technologies

http://www.moneyam.com/InvestorsRoom/posts.php?tid=20764#lastread

'Pivotal' year ahead for Allergy Therapeutics with key trial readouts (Video)
08:56 07 Mar 2018

Nick Wykeman and Manuel Llobet from Allergy Therapeutics plc (LON:AGY) caught up with Proactive Investors following the release of their interim results.

Allergy's continued to gain market share as it heads into a ‘pivotal’ twelve months.
Interim revenues rose by 4% to £42.2mln despite the pollen season being described as ‘abnormally weak’.

Headline or first glance data from the Phase III Pollinex Quattro Birch study in Europe is expected in the second half of the year along with first results from a Grass MATA MPL Phase II trial.

http://www.proactiveinvestors.co.uk/companies/stocktube/8851/-pivotal-year-ahead-for-allergy-therapeutics-with-key-trial-readouts-8851.html

https://www.youtube.com/watch?time_continue=201&v=ly_tv57J0XI

Allergy Therapeutics Results Video & investor meeting details
7th March 2018 | Allergy Therapeutics plc

Allergy Thereapeutics plc (LON:AGY) this morning released their Interim Results for the 6 months ended 31st December 2017. A short video is available below, with further explainer videos available on their company wall.

They reported a 4.4% increase in revenues, and this was against a backdrop of an unusually weak market: the pollen season was abnormally weak this year, leading to less demand for remedies & vaccinations. Their products Venomil and Acarovac Plus performed very well, and there have been a number of developments in AGY’s clinical trial pipeline.

Allergy Thereapeutics increased their R&D expenditure to £5.9m from £3.8m in the previous half. This was due to investment in their grass and Birch vaccine trials ( Grass MATA MPL Phase II and PQ Birch Phase III trials.

Professional Investors, UK wide meeting details
We are organising UK wide investor meetings with Allergy over the coming year, visiting London, Birmingham, Bristol, Manchester, Leeds, Edinburgh and Glasgow. The meetings are strictly for professional investors, and please contact us if you would like to meet them. We will be releasing dates shortly.

http://fmp-tv.co.uk/2018/03/07/allergy-therapeutics-results-video-investor-meeting-details/

07 March 2018

Hardman Research: Clinical development towards submission

Clinical development towards submission: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a 'Named Patient' basis. The Phase III trial, designed to obtain approval for PQ Birch as a biologic in Europe, is well advanced, and the Phase II PQ Grass trial will report data shortly. As explained in the February trading update, underlying 1H'18 sales growth, although weaker than expected due to a low pollen season in central Europe, suggests that AGY has continued to make market share gains.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/agy---interims---7th-march-2018.pdf

http://www.moneyam.com/action/news/showArticle?id=5882943